Brief: Alpine Immune Sciences Announces First Patient Dosed In Synergy, Alpn-101 Phase 2 Lupus Clinical Trial And $45 Million In Development Milestones Achieved Under Abbvie Collaboration
24/06/2021 13:36
June 24 (Reuters) - Alpine Immune Sciences Inc ALPN.O :
* ALPINE IMMUNE SCIENCES ANNOUNCES FIRST PATIENT DOSED IN
SYNERGY,
ALPN-101 PHASE 2 LUPUS CLINICAL TRIAL AND $45 MILLION IN
DEVELOPMENT MILESTONES ACHIEVED UNDER ABBVIE COLLABORATION
Source text for Eikon: ID:nBw4NWGC1a
Further company coverage: ALPN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpine Immune Sciences
See all newsAlpine Immune Sciences Inc reports results for the quarter ended in January - Earnings Summary
Brief: Alpine Immune Sciences Q1 EPS USD -0.28 Vs. IBES Estimate USD -0.41
Moves: Lazard hires veteran healthcare dealmaker Colocci as vice chairman
U.S. RESEARCH ROUNDUP-Cheesecake Factory, Netflix, Texas Roadhouse
US STOCKS-S&P 500, Nasdaq end sharply higher on soft inflation data, eyes on earnings